Clinical Trials Sponsored by Aerpio Therapeutics

Total 6381 results

Aerpio Therapeutics

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Aerpio Therapeutics

Completed

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

Retinal Vein Occlusion

United States
Aerpio Therapeutics

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

IBD

Canada
Aerpio Therapeutics

Completed

Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema (DME)

United States
Aerpio Therapeutics

Completed

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema (TIME-2)

Diabetic Macular Edema (DME)

United States
Aerpio Therapeutics

Completed

Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

Healthy
Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Emphysema | Chronic Pulmonary Obstructive Disease

Germany, Israel, Austria, France
Aeris Therapeutics

Completed

AeriSeal System for Lung Volume Reduction

Lung Diseases | Emphysema | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease (COPD)

Israel, Austria, France, Germany
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Advanced Emphysema

Germany
Aeris Therapeutics

Terminated

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Netherlands
Aeris Therapeutics

Terminated

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Israel
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Terminated

Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema (CV+/-)

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Withdrawn

Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema

Emphysema | Chronic Obstructive Pulmonary Disease (COPD)
Aeris Therapeutics

Completed

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Homogeneous Emphysema

United States
Aeris Therapeutics

Completed

Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

Israel
Aeris Therapeutics

Withdrawn

Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

Advanced Upper Lobe Predominant Emphysema
Aeris Therapeutics

Completed

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Pulmonary Emphysema

United States
Aeris Therapeutics

Terminated

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) (ASPIRE)

Pulmonary Emphysema

United States, Spain, France, Israel, Netherlands, Greece, Italy
Aeris Therapeutics

Completed

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | COPD

Israel
Aerin Medical

Completed

Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device

Chronic Rhinitis

United States
Aerie Pharmaceuticals

Completed

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United Kingdom, Spain, Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Poland
Aerin Medical

Completed

Posterior Nasal Nerve (PNN) Rhinitis Study

Chronic Rhinitis

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Aerie Pharmaceuticals

Completed

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Ocular Hypertension | Glaucoma, Open-Angle

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerin Medical

Completed

Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

Nasal Obstruction

United States
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

AR-12286 in Combination With Latanoprost

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Ocular Hypertension | Open Angle Glaucoma

United States
Aerin Medical

Active, not recruiting

RhinAer Procedure for Treatment of Chronic Rhinitis Study (RHINTRAC)

Chronic Rhinitis

United States
Aerie Pharmaceuticals

Completed

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-2)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Aerie Pharmaceuticals

Completed

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Aerie Pharmaceuticals

Completed

Study Evaluating Techniques for Measuring Tear Production (MTP)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Macular Edema

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (Rocket-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States

3

Subscribe